Congenital amegakaryocytic thrombocytopenia

Platelets are the cell fragments that stop bleeding. They are shed by large cells in the bone marrow called megakaryocytes. In this condition those cells are reduced or absent from birth, so there are far too few platelets — and over time the marrow stops making the other blood cells too.

The cause is a change in both copies of a gene called MPL, which builds the receiver that tells blood stem cells to make platelets. Without a working receiver the instruction never arrives.

Two courses are described, and which one a child has is largely determined by the specific gene change. Where the receiver has no function at all, platelet counts stay very low and every child so far has progressed to failure of the whole marrow. Where some function remains, platelets can rise during the first year and the course is milder and later.

The name is contested for a good reason. Newborns with other conditions can look clinically identical — including Fanconi anemia and dyskeratosis congenita before their own signs appear — and those need different treatment. Getting the genetics right first is not a formality.

Changes in both copies of MPL, inherited one from each parent. Nothing the parents did causes it.

Carrier parents and siblings are essentially unaffected — in the international cohort, platelet counts in heterozygous parents and siblings were normal with a single exception.

Severity tracks the specific mutation rather than luck. The same changes produce very similar courses in different families and different populations, which is unusual and clinically useful — it means the genetic result carries real information about what to expect.

Bleeding first. Pinpoint red spots and bruising at birth or in the first week are the presenting sign for most babies.

The gravest events are bleeds into the brain, and they cluster before and around birth. Their consequences are permanent — developmental delay was seen in several children in the international cohort, most of them with documented intracranial bleeding.

Then the rest of the marrow follows. Nearly every child with complete loss of receptor function progresses to failure across all three blood cell types, and it usually happens before age four.

One thing worth correcting: leukemia is not the main story here. Abnormal chromosome findings occurred in a minority, one child was diagnosed with a myelodysplastic neoplasm, and no overt leukemia was reported in the cohort during the period of record. The authors are explicit that although this condition is often described as pre-leukemic, only weak evidence supports that.

Diagnosis is not always immediate — in about a quarter of patients the low platelet count was not detected at birth, and some presented months or years later.

Platelet transfusions manage bleeding, but they are temporary and they do not change what the marrow can do.

Nothing else restores blood production. Immune-directed drugs produced no persistent response and a growth factor called IL-11 did not work. There is no equivalent here of the drug that transformed severe congenital neutropenia.

A transplant using another person’s blood-forming cells is the only curative treatment. In the international cohort, 38 of 51 patients had been transplanted with a transplant planned for another ten, and of the thirty with follow-up information, twenty-six had a positive outcome.

Timing is a clinical judgement with two documented positions, and both are reasonable. One is to transplant with the best-matched donor relatively soon after diagnosis. The other is that for the small group with milder mutations it may be appropriate to wait for the first signs of marrow failure — particularly where no family donor is available.

Getting the diagnosis right comes first. Children with an unclear picture should be tested for MPL changes, and conditions needing a different approach — or for which a transplant is not the answer at all — have to be excluded before proceeding.

This usually begins in the first days of life, with bruising and pinpoint bleeding in a newborn. For some families the most serious event has already happened before birth.

What follows is transfusion support while the diagnosis is worked out — and the working out matters, because several conditions look the same at this stage and need different treatment.

Then a decision about a transplant, made for a baby or a toddler, usually before the age of four. Parents are being asked to weigh a serious procedure against a marrow that the evidence says will almost certainly fail.

For children whose bleeding caused brain injury before or around birth, there is a second, separate set of consequences that a transplant does not address.

Here the donor genuinely is the treatment. Nothing else restores blood production, and nearly every child progresses to full marrow failure. That is a real difference from most conditions in this library, and from severe congenital neutropenia in particular — where a drug replaced the donor for almost every child.

Most of these transplants do not come from a sibling. In the largest series, 86 children across 40 centres between 2000 and 2018, only 23 used a matched sibling. Thirty-one used a matched unrelated donor, twenty-seven a mismatched unrelated donor, and five a mismatched relative — 73% from outside the sibling route.

And this is where the strongest evidence-supported donor argument in this whole batch sits, because it is about match quality rather than about need. Mismatched transplants in that cohort carried a 3.52-fold higher risk of death — 75% survival against 93% — and higher rates of the graft failing to take. A well-matched unrelated donor is not a consolation prize when there is no sibling. It is the thing that closes that gap.